BioSenic S.A. (0R55.L)
EUR 0.0
(0.0%)
EUR 0.0
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.21 EUR | -1135.29% |
| 2022 | -0.02 EUR | 97.21% |
| 2021 | -0.61 EUR | 40.2% |
| 2020 | -1.02 EUR | 7.27% |
| 2019 | -1.10 EUR | 41.18% |
| 2018 | -1.87 EUR | -0.54% |
| 2017 | -1.86 EUR | 2.11% |
| 2016 | -1.90 EUR | 11.21% |
| 2015 | -2.14 EUR | -26.63% |
| 2014 | -1.69 EUR | -26.12% |
| 2013 | -1.34 EUR | -25.23% |
| 2012 | -1.07 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.00 EUR | 0.0% |
| 2024 Q1 | 0.00 EUR | 104.91% |
| 2023 Q4 | -0.03 EUR | 0.0% |
| 2023 Q2 | -0.17 EUR | -103.11% |
| 2023 FY | - EUR | -1135.29% |
| 2023 Q1 | -0.08 EUR | -2162.16% |
| 2023 Q3 | -0.03 EUR | 84.41% |
| 2022 Q2 | -0.15 EUR | 0.0% |
| 2022 Q4 | -0.00 EUR | 0.0% |
| 2022 FY | - EUR | 97.21% |
| 2022 Q3 | -0.00 EUR | 97.53% |
| 2021 Q2 | -0.37 EUR | 0.0% |
| 2021 FY | - EUR | 40.2% |
| 2021 Q4 | -0.40 EUR | 0.0% |
| 2020 Q2 | -0.88 EUR | 0.0% |
| 2020 Q4 | -0.14 EUR | 0.0% |
| 2020 FY | - EUR | 7.27% |
| 2019 FY | - EUR | 41.18% |
| 2019 Q2 | -0.64 EUR | 0.0% |
| 2019 Q4 | -0.46 EUR | 0.0% |
| 2018 Q4 | -0.70 EUR | 0.0% |
| 2018 FY | - EUR | -0.54% |
| 2017 FY | - EUR | 2.11% |
| 2016 FY | - EUR | 11.21% |
| 2015 FY | - EUR | -26.63% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 FY | - EUR | -26.12% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | -25.23% |
| 2012 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Boiron SA | 2.06 EUR | 110.194% |
| Laboratorios Farmaceuticos Rovi, S.A. | 3.20 EUR | 106.563% |
| Vetoquinol SA | 4.70 EUR | 104.468% |
| Valneva SE | -0.73 EUR | 71.233% |
| AB Science S.A. | -0.20 EUR | -5.0% |
| Nanobiotix S.A. | -1.08 EUR | 80.556% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 95.8% |
| Vivoryon Therapeutics N.V. | -1.12 EUR | 81.25% |
| ABIVAX Société Anonyme | -3.43 EUR | 93.878% |
| Formycon AG | 4.76 EUR | 104.412% |